Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 1.00 |
| ▸ | ACACA | Q13085 | 15/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462988 | 1.00 | ACACB (1.00) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL3465044 | 1.00 | ACACB (1.00) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6181355 | 0.97 | ACACB (0.94) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6498280 | 0.95 | ACACB (0.91) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6185409 | 0.94 | ACACB (0.89) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6181251 | 0.92 | ACACB (0.85) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL6182631 | 0.91 | ACACB (0.84) | ACACBACACAKDM4ELMNAKDM2B | |
| SCHEMBL6184144 | 0.89 | ACACB (0.81) | ACACBACACAKDM4EKDM2B | |
| SCHEMBL6183674 | 0.89 | ACACB (0.80) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6182473 | 0.89 | ACACB (0.80) | ACACBACACAKDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150265-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | Neuera Pharmaceuticals, Inc. (US) | 2010-02-10 | — | — | EP | claimed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | claimed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| EP-3129385-B1 | NEOSORAPHENS AND THEIR USE IN THE TREATMENT OR PREVENTION OF A VIRAL INFECTION OR OF A TH17-ASSOCIATED INFLAMMATORY AND/OR AUTOIMMUNE DISEASE | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170029436-A1 | NEOSORAPHENS | Helmoltz-Zentrum für Infektionsforschung GmbH (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2008140828-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE FOR TREATMENT OF NEURONAL HYPOMETABOLISM | ACCERA, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1478437-A1 | ACC INHIBITORS | Pfizer Products Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003072197-A1 | ACC INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | ACACB 312/4885ACACA 702/4885KDM4E 2299/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ACACB 312/4885ACACA 702/4885KDM4E 2299/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM4E 2140/4885 |
| US-20170029436-A1 | NEOSORAPHENS | IL17A, RORC, CD4 | ACACB 4226/4885ACACA 3545/4885KDM4E 2130/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | ACACB 949/4885ACACA 1144/4885KDM4E 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.